Report: uniQure Could Put Itself Up For Sale

uniQure NV QURE shares are trading higher by 6% in Monday's pre-market session following a Bloomberg report the company is exploring strategic options, including a potential sale.

uniQure is a gene therapy company exploring options amid interest from other pharmaceutical companies looking to expand in gene therapy.

The stock traded around $76.80 per share at time of publication after closing Friday at $72.55. The stock's 52-week higher is $78.02 and its 52-week low is $21.89.

Related Links:

6 Gene Therapy M&A Targets On The Radar

Sorrento Therapeutics Could IPO Its Scilex Unit

Posted In: NewsRumorsMedia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...